Research programme: cyclo-oxygenase-2 inhibitors - NitroMed

Drug Profile

Research programme: cyclo-oxygenase-2 inhibitors - NitroMed

Alternative Names: COX-2 inhibitors research programme - NitroMed; Cyclo-oxygenase-2 inhibitors research programme - NitroMed; Research programme: COX-2 inhibitors - NitroMed

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator NitroMed
  • Class Pyrazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Inflammation; Pain

Most Recent Events

  • 19 Mar 2008 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 06 Mar 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 30 Mar 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the Inflammation pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top